Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

FDA commissioner Stephen Hahnduring a press conference at the White House on Sunday. Photo: Pete Marovich/Getty Images

FDA commissioner Stephen Hahn said in a Twitter thread Monday night criticisms of his comments about granting an emergency use authorization (EUA) of convalescent plasma as a treatment for the coronavirus were "entirely justified."

The big picture: Hahn also addressed in his post the politicization of the FDA, in an apparent reference to President Trump and his trade adviser, Peter Navarro, accusing senior health officials of being part of the "Deep State" amid a decision to put the plasma treatment on hold.

  • Trump said at a news conference Sunday night the plasma "has proven to reduce mortality by 35%. Hahn echoed these remarks, saying: "What that means is -- and if the data continue to pan out -- 100 people who are sick with Covid-19, 35 would have been saved because of the administration of plasma."

What he's saying: Hahn said in his Twitter post that what he should have said better was that "the data show a relative risk reduction not an absolute risk reduction.

  • "The authorization of emergency use of convalescent plasma is not a final approval. FDA will continue to monitor its use and will revoke authorization if needed. We feel broader use of plasma will truly benefit many patients but will require further study," he added.
  • "The convalescent plasma decision was made entirely by FDA scientists. We at FDA do not permit politics to enter into our scientific decisions. This happens to be a political season but FDA will remain data driven. On behalf of FDA‘s 18,000 career employees, I want to reassure the American public about this commitment."

Of note: Hahn stressed that the decision was based on "significant data" from reliable sources including the Mayo Clinic, "plus a century of experience with convalescent plasma."

  • "We unfortunately do not have randomized trials for convalescent plasma but must make decisions based on what we do have from the Mayo Clinic expanded access program," he said.
  • "They had confidence that convalescent plasma has potential to benefit many sick patients and the safety profile is well defined.
"Media coverage of FDA’s decision to issue emergency authorization for convalescent plasma has questioned whether this was a politically motivated decision. The decision was made by FDA career scientists based on data submitted a few weeks ago."

Editor's note: This article has been updated with new details throughout.

Go deeper

Updated 10 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Brendan Lynch/Axios

  1. Health: Coronavirus cases aren't budging — even after vaccinations doubled— Health care workers feel stress, burnout more than a year into the pandemic — Handful of "breakthrough" COVID cases occurred in nursing homes, CDC says.
  2. Vaccines: Johnson & Johnson's vaccine production problems look even bigger — All U.S. adults now eligible for COVID-19 vaccine.
  3. Political: Watchdog says agency infighting increased health and safety risks at start of pandemic.
  4. World: EU regulator: Benefits of J&J vaccine outweigh risk of rare blood clots.
  5. Variant tracker: Where different strains are spreading.
Jan 14, 2021 - Health

Coronavirus deaths climbing while country deals with political unrest

Expand chart
Data: The COVID Tracking Project; Map: Andrew Witherspoon/Axios

Coronavirus deaths continue to reach tragic heights while the country grapples with a vaccine rollout, an impeachment and ongoing civil unrest.

Jan 14, 2021 - Health

SoCal on the brink

A COVID-19 ICU at Martin Luther King Jr. Community Hospital in the Willowbrook neighborhood of Los Angeles. Photo: Patrick T. Fallon/AFP via Getty Images

Southern California's COVID outbreak is in a terrible place, and hospitals haven't even been hit with a wave of potential infections from Christmas and New Year's.

The big picture: Hospitalizations have stabilized, but public health officials say that's just from infections linked to Thanksgiving, the L.A. Times reports.